Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dose Response Curve: Conventional Versus Nonmonotonic

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...

Dosage Regimens: Designs and Approaches

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...

Dose-Response Relationship: Overview

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Design, simulate, refine: simulation-guided clinical trials for accelerated drug development.

Nature reviews. Drug discovery·2026

Same author

Informative Futility Rules Based on Conditional Assurance.

Statistics in medicine·2026

Same author

Correspondence about the article "Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia: the REMAP-CAP corticosteroid domain randomized clinical trial": author's reply.

Intensive care medicine·2025

Same author

Clinical correlation of SARS-CoV-2 wastewater passive sampling in long-term care facilities and wastewater treatment plants.

Environmental advances·2025

Same author

Implementing Wastewater-Based Epidemiology for Long-Read Metagenomic Sequencing of Antimicrobial Resistance in Kampala, Uganda.

Microorganisms·2025

Same author

Multi-pathogen wastewater surveillance in Malawi: An assessment of culture-based, RT-PCR, and long-read metagenomics methods with multiple ongoing outbreaks.

The Science of the total environment·2025

Search research articles

Related Experiment Video

Updated: May 25, 2026

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

A bayesian dose-finding design adapting to efficacy and tolerability response.

S Krishna Padmanabhan¹, Scott Berry, Vladimir Dragalin

¹Pfizer, Collegeville, Pennsylvania, USA. SKrishna.Padmanabhan@Pfizer.com

Journal of Biopharmaceutical Statistics

|January 19, 2012

Summary

This study introduces an adaptive Bayesian design for drug development, balancing treatment efficacy and tolerability. Simulations show this novel method efficiently identifies optimal drug doses, aiding risk-benefit assessment.

More Related Videos

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Published on: May 19, 2023

Related Experiment Videos

Last Updated: May 25, 2026

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Published on: May 19, 2023

Area of Science:

Biostatistics
Clinical Trial Design
Pharmacology

Background:

Dose-finding studies are crucial for drug development, aiming to balance therapeutic efficacy with patient safety.
Traditional designs may not optimally capture the complex relationship between dose, efficacy, and tolerability.
A need exists for adaptive designs that efficiently navigate this trade-off.

Purpose of the Study:

To propose and evaluate a novel adaptive Bayesian design for dose-finding studies.
To explicitly model the trade-off between a continuous efficacy variable and a dichotomous tolerability variable.
To identify a target dose that maximizes efficacy while maintaining safety.

Main Methods:

Developed an adaptive Bayesian design incorporating continuous efficacy and dichotomous tolerability.
Utilized simulations to assess design performance under various scenarios.
Incorporated features such as stopping rules, adaptive allocation, and dose-response estimation for both efficacy and tolerability.

Main Results:

The proposed adaptive Bayesian design demonstrated high efficiency in simulations.
The design effectively characterized the risk-benefit profile of a drug.
Performance was evaluated across diverse simulated scenarios.

Conclusions:

The novel adaptive Bayesian design offers an efficient approach for dose-finding studies.
This method facilitates robust risk-benefit assessment during drug development.
The design is adaptable to various settings with continuous efficacy and dichotomous safety variables.